Member Info for Bazzaman

He had the shares sun 2p & sold 50% at 10.55p, 40% at 15p & 10% at 15.6p. He's happy with his lot.

Says he sold the remainder of his shares on OO this morning. He believes that COVID will be gone like SARS did in a few months and therefore the need for tests/vaccines will disappear. He doesn't expect a second wave. He likes OO as a company and will look to get back in at around 9p which he expects will happen. Everyone entitled to their opinion, I don't agree with him. Still expect many more months of this virus. GLA

NST - 16p sell /16.2p buy - sounds about right to me.

FinnCap's target price does NOT include any revenue from COVID challenger study which they estimate at c£7m per study with OO prospect of doing 5-6 p.a. They only include £9m rev for this year for lab testing whereas 1m tests would generate £70m. Genomic rev not until 2021.
So a quick view gives an extremely low/conservative estimate at 19p IMHO. Plenty of upside to go for. GLA

It's free to register on their web-site. You can then access the 25 page report which is an interesting read. GLA

Have a read of the rules, you might find them interesting. https://www.londonstockexchange.com/companies-and-advisors/aim/publications/rules-regulations/aim-rules-for-companies.pdf

Cathal Friel, Executive Chairman of Open Orphan, said:

“Open Orphan is now a fast growing, and soon to be profitable, specialist CRO pharmaceutical services business with a market leading position in the rapidly expanding market of testing vaccines and antivirals. We are delighted by the heavily oversubscribed fundraise which has brought many new leading blue-chip institutional shareholders to our share register.

As a result of Covid-19, we are seeing unprecedented growth opportunities as pharma, biotech and governments around the world focus funding on finding solutions to Covid-19 and other respiratory diseases. As such, we’re developing several new revenue streams including by speeding up the development of both a seasonal coronavirus and a Covid-19 virus challenge study model to capitalise upon the Company’s inbound demand from Covid-19 vaccine developers globally. We have also opened up our laboratory services offering to third party pharma and biotech companies, as in the case of the recently announced Nearmedic contract, and from our state-of-the-art viral laboratory have launched a transformational Covid-19 antibody testing service which, unlike the home and online testing kits, offers 100% accuracy and the potential to complete up to 3,000 tests per day on a single machine. We believe that the Company has the pipeline to potentially sign up to six Covid-19 related challenge study contracts in 2020 with a further six potential contracts in 2021.

It is an exciting time at Open Orphan, and we are looking to capitalise on the opportunity to deliver rapid growth in the near term by converting some of our c. £160m pipeline of revenue opportunities.”

I don't think CF could resist the £ signs coming with COVID, expect many deals in the coming days/weeks. He is entitled to change his mind IMHO. Roll on next week, looking forward to the next RNS. GLA

https://www.investorschronicle.co.uk/comment/2020/05/21/exploiting-cash-rich-value-plays/

Won't be us if it is a finger prick

Interesting update, thanks for all your efforts.

Not for me, Muddy Waters slammed them. They think it will head to zero. Happy to wait for FUM to sky rocket. GLA

just as CF wanted it, until the big unveiling of the details of the partnership with Quotient. RNS on Tuesday looks likely based on his recent presentations & indeed if he is ready. GLA

Part 3 https://twitter.com/ValueAimTrader/status/1263042822879485953/photo/1

Hi Bamps, good news for you. My top 3 performing are GGP, ORPH & SLP and still expecting more good news for all of them. My staple shares TW. INL, WJG will recover once the country gets back to some normality. Thanks for your suggestions as well. BOL

I agree that this should challenge recent highs, a great start to the day - let us hope it stays above the 50p mark. BOL

Good luck Tom

Hi Tom et al. A know you guys like researching other shares and I think it might be worth looking at ORPH & SLP. No guarantees but like GGP probably worth a view. IMHO still some way to go but as always DYOR.

Looks like a blue start

Don't follow him for his tips but I subscribe to avoid the frauds he exposes. GLA